FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives
This article was originally published in The Pink Sheet Daily
Executive Summary
In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.
You may also be interested in...
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.